In Vitro: Crovalimab (SKY59; RO7112689; 0-100 μg/mL) inhibits haemolysis in classical pathway and reactive lysis systems.
In Vivo: Crovalimab (SKY59; RO7112689; 20 mg/kg; iv; only once at day 0) completely prevents accumulation of plasma C5 in cynomolgus monkeys. SKY59-IgG1 (SG115) shows slower clearance: 1.87 mL/day/kg. Crovalimab (20 mg/kg; iv; a single dose) stably suppressed complement activity in plasma for 8 weeks. Crovalimab (5 mg/kg by iv at day 0 and 2 mg/kg by sc at day 7, 21, 35, 49, and 63) causes over 20% of serum hemolytic activity in the cRBC lysis assay to correlate with events such as dysphagia and dramatic increases in lactate dehydrogenase (LDH) and alanine aminotransferase (ALT) levels.